Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?
Zacks Investment Research | Oct 29, 2017 10:17PM ET
Myriad Genetics, Inc. (NASDAQ:MYGN) is scheduled to report first-quarter fiscal 2018 results on Nov 7, after the closing bell.
Last quarter, the company posted a positive earnings surprise of 15.4%. Moreover, Myriad Genetics beat the Zacks Consensus Estimate in three of the trailing four quarters, the average being 6.2%.
Let’s take a look at how things are shaping up prior to this announcement.
Key Catalysts
Similar to last quarter, Myriad Genetics is expected to gain from strong Molecular Diagnostics performance led by solid contributions from the GeneSight and EndoPredict tests. The Zacks Consensus Estimate for Molecular Diagnostics revenues of $170 million reflects an increase of 3% from the year-ago quarter.
We are also upbeat about management’s expectations of double-digit volume growth in fiscal 2018 for GeneSight, Vectra DA, Prolaris and EndoPredict revenues, all of which make up most of the Molecular Diagnostics portfolio.
Myriad Genetics, Inc. Price and EPS Surprise
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.